Human Papillomavirus Genotypes in High-Grade Cervical Lesions in the United States
Authors:
- Susan HaririSHSusan Hariri
- Elizabeth R. UngerEUElizabeth R. Unger
- the HPV-IMPACT Working GroupTGthe HPV-IMPACT Working Group
Open Access
- 8 October 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 206 (12) , 1878-1886
Abstract
Background. Two vaccines protect against human papillomaviruses (HPV) 16 and 18, which cause 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ (CIN2+). Monitoring HPV types in CIN2+ may be used to assess HPV vaccine impact. Methods. As part of a multisite vaccine impact monitoring project (HPV-IMPACT), biopsy specimens used to diagnose CIN2+ were obtained for HPV DNA typing for women aged 18–39 years. Results. Among 4,121 CIN2+ cases reported during 2008–2009 in 18- to 39-year-old women 3058 (74.2%) were tested; 96% were HPV DNA positive. HPV 16 was most common (49.1%), followed by HPV 31 (10.4%) and HPV 52 (9.7%). HPV 18 prevalence was 5.5% overall. Proportion of CIN2+ cases associated with HPV 16/18 was highest (56.3%) in 25- to 29-year-old women. HPV 16/18-associated lesions were less common in non-Hispanic blacks (41.9%) and Hispanics (46.3%) compared with non-Hispanic whites (59.1%) (P < .0001); the difference remained significant when adjusted for covariates. Compared to non-Hispanic whites, HPV 35 and 58 were significantly more common in non-Hispanic blacks (14.5% vs 4.2%; 12.3% vs 3.4%) and HPV 45 was higher in Hispanics (3.7% vs 1.5%). Conclusions. Age and racial/ethnic differences in HPV type distribution may have implications for vaccine impact and should be considered in monitoring trends.Keywords
This publication has 23 references indexed in Scilit:
- The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesionsCancer Causes & Control, 2011
- Efficient DNA Extraction for HPV Genotyping in Formalin-Fixed, Paraffin-Embedded TissuesThe Journal of Molecular Diagnostics, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Committee Opinion No. 463: Cervical Cancer in Adolescents: Screening, Evaluation, and ManagementObstetrics & Gynecology, 2010
- Post-licensure monitoring of HPV vaccine in the United StatesVaccine, 2010
- Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United StatesJNCI: Journal of the National Cancer Institute, 2009
- 2006 Consensus Guidelines for the Management of Women With Cervical Intraepithelial Neoplasia or Adenocarcinoma In SituJournal of Lower Genital Tract Disease, 2007
- Human papillomavirus and cervical cancerThe Lancet, 2007
- Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysisBritish Journal of Cancer, 2003
- Active Bacterial Core Surveillance of the Emerging Infections Program NetworkEmerging Infectious Diseases, 2001